New treatments needed for patients with refractory triple-class multiple myeloma



Based on data from the Connect MM Disease Registry presented to the American Society of Hematology 2021 Annual Meeting and Exhibition. The study demonstrates a need for new, tolerable and effective therapeutic agents to address the burden of disease in patients with MM, the researchers say.

“Resistance to treatment remains a challenge for most patients with multiple myeloma and their health-related outcomes and quality of life deteriorate with each line of treatment,” said Robert Rifkin, MD, medical director of biosimilars for McKesson, associate chair of hematology and myeloma disease research head of the US Oncology Network and hematologist of the Rocky Mountain Cancer Centers, in a press release. “Patients refractory to immunomodulatory drugs, proteasome inhibitors and anti-CD38 antibodies, or triple-class refractory, have a particularly poor prognosis and a high disease burden. “

Resistance to treatment is a common challenge faced by most MM patients during their disease. Patients with MM who are refractory to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies have a poor prognosis, with the holistic burden poorly understood, the researchers say.

To conduct the study, researchers collected data between September 28, 2009 and February 4, 2021. Eligible participants included patients 18 years of age or older at their first documented diagnosis of MM, which later became RCD. the course of the disease. Criteria from the International Myeloma Working Group were used to determine whether the patient’s disease was refractory.

The analysis included 240 patients with a mean age at baseline of 68.1 years and a mean time from initial diagnosis of 64.1 months. Of the study participants, 63.3% had previously received a stem cell transplant.

For all patients, median overall survival (OS) was 8.9 months, while OS for participants who received more than 4 prior lines of treatment was 8 months. HRQoL analysis demonstrated a clinically significant decrease in HRQoL from baseline after index date based on EQ-5D utility index, EVA EQ-5D and the total FACT-G score.


Tang D, Hari P, Ramasamy K, et al. Real-world treatment models and clinical, economic, and humanistic burden in refractory triple-class multiple myeloma: Analysis of the Connect® Multiple Myeloma (MM) Disease Registry. Presented at: ASH Annual Meeting and Exposition 2021. Accessed December 10, 2021.



Comments are closed.